Purpose: To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularization in rats.
Materials and Methods: Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterization on the corneas of 16 eyes from 16 male Long-Evans (LE) rats. For the following 7 days, the 10 eyes in the treatment group received twice daily instillation of Bevacizumab 4mg/ml drops while the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.
Results: In the Bevacizumab treated eyes, neovascularization covered, on average, 38.2 ±15.5% (mean ± standard deviation[SD]) of the corneal surface compared with 63.5 ± 5.0% (mean ± SD) in the control group (p<0.02, Mann-Whitney U test).
Conclusion: Topically administered Bevacizumab (Avastin) at a concentration of 4mg/ml limits corneal neovascularization following chemical injury in the male Long-Evans rat model.